4.4 Article

Different distribution of NOTCH1 mutations in chronic lymphocytic leukemia with isolated trisomy 12 or associated with other chromosomal alterations

Journal

GENES CHROMOSOMES & CANCER
Volume 51, Issue 9, Pages 881-889

Publisher

WILEY
DOI: 10.1002/gcc.21972

Keywords

-

Funding

  1. Instituto Carlos III [FI08/00234]
  2. Red Tematica de Investigacion Cooperativa en Cancer (RTICC) [RD06/0020/0039]
  3. Instituto de Salud Carlos III (ISCIII)
  4. Spanish Ministry of Science and Innovation
  5. Spanish Comision Interministerial de Ciencia y Tecnologia (CICYT)
  6. European Regional Development Fund (ERDF) [SAF08-03630]
  7. Generalitat de Catalunya [2009SGR992]
  8. Spanish Ministry of Science and Innovation (MICINN) through the Instituto de Salud Carlos III (ISCIII)
  9. Red Tematica de Investigacion del Cancer (RTICC) del ISCIII

Ask authors/readers for more resources

Chronic lymphocytic leukemia (CLL) is the most common leukemia among adults in Western countries. Chromosomal abnormalities commonly found using conventional cytogenetics and FISH are del(11)(q22-23), trisomy 12, del(13)(q14), and del(17)(p13). Trisomy 12 is the most frequent numerical abnormality in CLL. It can appear isolated or associated with other chromosomal aberrations, including t(14;18)(q32;q21) and trisomy 18. The aim of this study was to determine whether CLL patients with isolated trisomy 12 or associated with other chromosomal alterations have different clinico-pathological features, including a different distribution NOTCH1 mutation. Patients were classified into four groups: Group 1, isolated trisomy 12 (n = 14); Group 2, trisomy 12 plus trisomy 18 (n = 4); Group 3, trisomy 12 plus t(14;18) (n = 8); and Group 4: patients with trisomy 12 plus other abnormalities not involving BCL2 (n = 28). The Binet stage and expression of ZAP70 were significantly different among cytogenetic groups. NOTCH1 mutations were detected in 6/12 (50%) patients from Group 1, 4/25 (16%) patients from Group 4, and in no patient from groups 2 and 3 (P = 0.020). Patients in Group 2 had a more rapid disease progression (median Treatment-free Survival 2 months) as against patients from Groups 1 (50 months), 3 (69 months), or 4 (68 months; P = 0.001). These findings indicate that the distribution of NOTCH1 mutations in CLL with trisomy 12 is heterogeneous and that the presence of additional chromosomal abnormalities such as trisomy 18 could change the prognosis of these patients. (C) 2012 Wiley Periodicals, Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available